{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-21-032255","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2021-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.685759+00:00","generated_at":"2026-06-29T01:53:52.331267+00:00","sec_items":["4.01","5.02","5.03","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Brooklyn ImmunoTherapeutics appoints CMO Roger Sidhu, outlines gene editing strategy; appoints Marcum as auditor","bullets":["Roger Sidhu appointed CMO effective Sept 20, 2021; receives option for 161,300 shares and RSU for 80,650 shares, base salary $447,200.","Bylaws amended to remove CFO position; VP of Finance Sandra Gurrola serves as principal financial officer.","Marcum LLP appointed as new independent auditor for FY2021 after dismissal of Baker Tilly.","Shareholder update call: plans to use iMSCs for allogeneic bone marrow transplants, gene editing for solid tumors and monogenic disorders.","Dr. Sidhu previously at Kite Pharma (Gilead), Roivant Sciences, Cell Design Labs, Amgen; M.D. from Queen's University."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-21-032255","json":"https://secwatch.observer/filing/0001140361-21-032255.json","markdown":"https://secwatch.observer/filing/0001140361-21-032255.md","text":"https://secwatch.observer/filing/0001140361-21-032255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036121032255/0001140361-21-032255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036121032255/brhc10029142_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:53:52.331267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e40459f78c","claim":"Roger Sidhu was appointed as Chief Medical Officer at Ernexa Therapeutics Inc..","evidence_excerpt":"On September 22, 2021, we announced that Roger Sidhu had been appointed as our Chief Medical Officer, effective September 20, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036121032255/0001140361-21-032255-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}